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Background:  Chemerin is a novel adipokine that is associated with inflammation and adipogenesis. However, it remains un-
clear whether chemerin is involved in patients with cardiovascular disease. We investigated whether the serum chemerin levels 
of Korean patients with coronary artery disease correlated with specific cardiometabolic parameters.
Methods:  In total, 131 patients, all of whom had coronary artery stenosis exceeding 50%, participated in this study. Their serum 
chemerin levels and cardiometabolic parameters were measured. The serum chemerin levels of two groups of patients were com-
pared; those with one stenotic vessel (n=68) and those with multiple stenotic vessels, including left main coronary artery disease 
(n=63). 
Results:  Serum chemerin levels correlated positively with the degree of coronary artery stenosis and fasting glucose, triglycer-
ide, total cholesterol, low density lipoprotein cholesterol, and high sensitive C-reactive protein levels. The group with multiple 
stenotic vessels, including left main disease, had higher chemerin levels than the group with one stenotic vessel (t=-2.129, 
P=0.035). Multiple binary logistic regression showed chemerin was not an independent risk factor of multiple vessel disease 
(odds ratio, 1.018; confidence interval, 0.997 to 1.040; P=0.091).
Conclusion:  Serum chemerin levels have a significant correlation with several cardiometabolic risk factors and the degree of 
coronary artery stenosis in Korean patients with coronary artery disease. However, multiple binary logistic regression showed 
chemerin was not an independent risk factor of multiple vessel disease. Additional investigations are necessary to fully elucidate 
the role of chemerin in cardiovascular disease. 
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INTRODUCTION
Due to the essential role obesity plays in the pathogenesis of 
metabolic syndrome, a syndrome that is associated with car-
diovascular morbidity, considerable interest has arisen in un-
derstanding the role obesity plays in cardiovascular disease 
[1]. Adipose tissue is no longer thought to only store excess 
energy; rather, it appears to be an active endocrine organ that 
produces many cytokines, which are known as adipokines [2-
6]. These adipokines appear to have systemic effects on the 
brain, liver, muscles, β-cells, gonads, lymphoid organs, and 
vasculature [7]. Many studies have examined the role adipose 
tissue plays in the development of coronary artery disease in 
patients with metabolic syndrome [8-13], and it is now under-
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stood that adipose tissue can cause vascular complications ei-
ther directly by causing atherosclerosis and inducing inflam-
matory responses, or indirectly by promoting the development 
of insulin resistance [14]. These atherosclerosis-inducing path-
ways are mediated by various adipokines, including adiponec-
tin, leptin, retinol binding protein-4 and resistin [8-12]. Anal-
yses of additional adipokines may help us to further under-
stand the pathogenesis of insulin resistance and its cardiovas-
cular complications. 
  Chemerin is a recently discovered 16 kDa chemoattractant 
protein that acts as a ligand for the G-protein receptor CMKLR1 
(ChemR23 or DEZ) [15,16]. It is secreted by adipose tissue as 
prochemerin (18 kDa) [16] and is transformed into an active 
protein by serine protease cleavage of its C-terminal fragment 
[17]. In its active form, chemerin regulates the immune system 
and participates in inflammation by promoting the recruitment 
of tissue macrophages and plasmacytoid dendritic cells [15,18]. 
Chemerin is also associated with adipogenesis, as studies with 
Psammomys obesus have shown that while both chemerin and 
CMKLR1 are expressed by all tissues, their expression is par-
ticularly high in the liver, kidney, and adipose tissue [19]. More-
over, while undifferentiated adipose tissue only expresses low 
levels of chemerin and CMKLR1, both molecules are expressed 
at progressively higher levels by differentiated adipocytes [15]. 
The knockdown of chemerin or CMKLR1 expression in pre-
adipocytes severely impairs their differentiation and reduces 
the expression of genes involved in glucose and lipid metabo-
lism [15]. These observations suggest that chemerin may par-
ticipate in insulin resistance and its cardiovascular complica-
tions.
  As mentioned above, chemerin is associated with inflam-
mation, adipogenesis, glucose, and lipid metabolism, all of 
which may contribute to the development of diabetic cardio-
vascular complications, especially atherosclerosis [15,18,19]. 
Therefore, we hypothesized that chemerin levels might be re-
lated to other cardiometabolic markers and that an increase in 
chemerin might reflect the degree of atherosclerotic burden. 
To further address this question, we examined whether the 
chemerin levels in Korean patients with coronary artery dis-
ease correlate with specific cardiometabolic parameters.
METHODS
Subjects
Of the patients who underwent coronary angiography at Kei-
myung University Dongsan Hospital, Daegu, Korea from No-
vember 2006 to April 2007, 131 were proven by coronary an-
giography to have meaningful stenosis (≥50%) and were re-
cruited. Patients who did not have infections or renal or liver 
failure were eligible for the study. The medical history of each 
patient was determined by a questionnaire. The present study 
was approved by the local Ethical Review Committee of the 
Keimyung University School of Medicine. All participants gave 
informed consent. 
Anthropometric, blood pressure, and biochemical 
measurements
All patients provided their personal information, and their 
height, weight, and waist circumference were measured. Body 
mass index (BMI) was calculated (kg/m
2). Blood pressure was 
measured by an electronic device (FA-94H; Fanics, Korea) af-
ter sitting for 5 minutes. Blood was drawn in the morning after 
a 12-hour fast. The fasting serum glucose levels were measured 
by using the glucose oxidase method (Cobas Integra 800; 
Roche, Basel, Switzerland). Fasting serum insulin concentra-
tions were measured by a radioimmunoassay kit (Insulin 
Myria; TechnoGenetics, Milano, Italy). The homeostasis mod-
el of assessment of insulin resistance (HOMA-IR) was calcu-
lated as fasting in  sulin×(fasting glucose/22.5). The levels of 
the following biochemical markers were measured by enzy-
matic methods (Cobas Integra 800): serum triglyceride, total 
cholesterol, and high density lipoprotein (HDL) and low den-
sity lipoprotein (LDL) cholesterol. High sensitive C-reactive 
protein (hsCRP) concentrations were measured using the la-
tex method (TBA-200  FR; Tosiba, Tokyo, Japan). Serum ho-
mocysteine concentrations were measured using an Axsym 
(Abbott, Abbott Park, IL, USA). The separated sera were 
stored at -70°C until the chemerin levels could be measured 
using a commercially available ELISA (R&D, Minneapolis, 
MN, USA) as previously described [19]. The capture antibody 
and detection antibody were used. Intra- and inter-assay coef-
ficients of variance for the che  merin ELISA were 5.0% and 
10.0%, respectively. The sensitivity of the ELISA assay was 1 to 
10 ng/dL, and the midrange of the assay was 5 ng/dL. This kit 
can detect human chemerin concentration by 0.5 ng/dL at 
least.
Coronary angiogram
Angiographic images were reviewed by an experienced cardi-
ologist who was unaware of the patient’s biochemistry results. 250
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As outlined in the Duke coronary artery index [20,21], we de-
fined significant stenosis as >50% of the lumen diameter. The 
degree of stenosis of the diseased vessels served as a severity 
index. Patients were divided into two groups; those with one 
stenotic vessel (n=68) and those with multiple stenotic vessels, 
including left main disease (n=63). 
Statistical analysis
The data are expressed as mean±standard deviation. We per-
formed Student’s t-test to compare chemerin levels and other 
metabolic factors in patients divided according to the number 
of stenotic vessels, and checked multiple binary logistic regres-
sion analysis (95% confidence interval) on risk of multiple ves-
sel stenosis. We performed Pearson’s correlation analyses be-
tween chemerin and cardiometabolic factors using SPSS ver-
sion 12.0 software for Windows (SPSS Inc., Chicago, IL, USA). 
P values of less than 0.05 were considered statistically signifi-
cant.
RESULTS 
Clinical and metabolic subject characteristics 
Table 1 shows the clinical characteristics of the 131 study sub-
jects, of whom 86 (65.6%) and 45 (33.6%) were men and wom-
en, respectively. In total, 69 (52.7%) patients were smokers, 32 
(24.4%) had diabetes and 85 (64.9%) had hypertension. Mean 
BMI was 24.1±2.8 kg/m
2. Thirty-five (26.7%) patients were 
overweight (BMI 23 to 24.9 kg/m
2) and 51 (39.0%) patients 
were obese (BMI >25 kg/m
2). Angiography showed that 68 
(49.8%) patients had one vessel disease, 39 (32.2%) had two 
vessel disease, 16 (12.3%) had triple vessel disease, and 8 (5.8%) 
had left main disease. In addition, 84 (64.1%) patients were 
being treated with anti-platelet agents, 32 (24.4%) patients were 
being treated with an oral hypoglycemic agent, 85 (64.9%) pa-
tients were being treated with an antihypertensive drug, and 
48 (36.7%) patients were being treated with statins before en-
rollment.
Correlation between serum chemerin concentrations and 
cardiometabolic parameters
There were significant but weak correlations between serum 
chemerin concentrations and fasting glucose, triglyceride, to-
tal cholesterol, LDL-cholesterol and hsCRP (Table 2). Howev-
er, serum chemerin concentrations did not correlate signifi-
cantly with fasting insulin, HDL-cholesterol or homocysteine 
levels, BMI, waist circumference, HOMA-IR and systolic and 
diastolic blood pressure. 
Correlation between serum chemerin concentrations and 
coronary angiographic findings
To determine whether serum chemerin concentration is asso-
ciated with coronary artery disease, we analyzed the correla-
tion between serum chemerin concentrations and coronary 
stenosis (%) in all participants. Fig. 1 shows how serum che-
merin concentrations correlate with the degree of coronary ar-
tery stenosis. We measured a significant positive correlation, 
Table 1. Clinical and metabolic characteristics of subjects 
Characteristic Value
No. 131
Age, yr 62.2±10.0
Sex, M/F 86/45 (65.6/33.6)
BMI, kg/m
2 24.1±2.8
Waist circumference, cm 87.0±7.2
Fasting glucose, mmol/L 5.9±2.1
Fasting insulin, pmol/L 9.3±1.4
Total cholesterol, mmol/L 4.6±1.2
Triglyceride, mmol/L 3.58±1.9
HDL-cholesterol, mmol/L 1.2±0.3
LDL-cholesterol, mmol/L 2.92±1.0
HOMA-IR 2.3±1.9
Chemerin, ng/dL 82.9±7.5
hsCRP, mg/dL 0.46±1.07
Homocystein, μmol/L 13.3±7.6
SBP, mm Hg 120.6±18.7
DBP, mm Hg 73.9±10.3
Stenosis (%) 79.75±14.2
Diabetes 32 (24.2)
Smoker 69 (52.7)
Medication history
Anti-platelets 84 (64.1)
Oral hypoglycemic agents 32 (24.4) 
Antihypertensive drugs 85 (64.9)
Statins 48 (36.7)
Data are presented as mean±standard deviation or number (%).
BMI, body mass index; HDL, high density lipoprotein; LDL, low den-
sity lipoprotein; HOMA-IR, homeostasis model of assessment of in-
sulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systol-
ic blood pressure; DBP, diastolic blood pressure; Stenosis (%), percen-
tage of coronary artery stenosis.251
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albeit weak, between these two parameters (r=0.0200, P=0.022). 
Moreover, the group with multiple vessel disease, including 
left main disease, showed higher age and chemerin, LDL, and 
CRP levels than the one vessel disease group (Table 3). How-
ever, Table 4 depicts that chemerin level is not an independent 
risk factor in multiple vessel disease. 
DISCUSSION
Accumulating evidence has suggested that adipokines play an 
Table 2. Correlation between chemerin and cardiometabolic 
parameters
Parameter r P value
BMI -0.104 0.238
Waist circumference -0.089 0.347
Fasting glucose 0.208 0.032
Fasting insulin 0.045 0.679
Triglyceride 0.208 0.018
Total cholesterol 0.177 0.043
HDL-cholesterol -0.149 0.090
LDL-cholesterol 0.198 0.025
HOMA-IR 0.096 0.402
Log hsCRP 0.209 0.018
Homocystein 0.134 0.173
SBP -0.035 0.692
DBP -0.019 0.827
The P values are from Pearson’s correlations.
BMI, body mass index; HDL, high density lipoprotein; LDL, low den-
sity lipoprotein; HOMA-IR, homeostasis model of assessment of in-
sulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systol-
ic blood pressure; DBP, diastolic blood pressure. 
Fig. 1. Correlation between chemerin levels and the degree of 
coronary artery stenosis. Pearson’s correlation coefficient=0.21; 
P<0.022.
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Table 3. Characteristics in patients divided according to the 
number of stenotic vessels and presence of left main lesions
Parameter
One vessel 
disease 
(n=68)
Multiple ves-
sel disease
a 
(n=63)
t (P value)
Chemerin, ng/dL 79.5±18.1 86.6±20.4 -2.129 (0.035)
Age, yr 60.1±9.9 64.5±9.7 -2.536 (0.012)
BMI, kg/m
2 24.4±3.1 23.9±2.5 1.010 (0.314)
HDL, mmol/L 1.2±0.3 1.2±0.2 1.030 (0.305)
LDL, mmol/L 2.8±1.0 3.1±1.0 -2.031 (0.044)
TG, mmol/L 1.6±0.8 1.6±0.9 0.042 (0.967)
HbA1c, % 6.4±1.17 6.1±1.1 1.217 (0.227)
Homocystein 13.3±8.3 13.2±6.8 0.051 (0.960)
SBP, mm Hg 119.6±16.3 121.3±21.1 -0.420 (0.675)
DBP, mm Hg 73.1±9.2 74.7±11.4 -0.862 (0.390)
Insulin, pmol/L 10.8±10.0 7.6±4.7 1.968 (0.053)
Fasting glucose, mmol/L 5.6±1.3 6.3±2.7 -1.786 (0.079)
HOMA 2.6±2.2 1.9±1.6 1.511 (0.135)
hsCRP, mg/dL 0.3±0.28 0.7±1.5 -2.189 (0.032)
Data are presented as mean±standard deviation. 
Patients were divided according to one stenotic vessel (one vessel dis-
ease) or multiple stenotic vessels (multiple vessel disease). 
The P values are from Student’s t-test. 
BMI, body mass index; HDL, high density lipoprotein; LDL, low den-
sity lipoprotein; HOMA, homeostasis model of assessment; hsCRP, 
high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, 
diastolic blood pressure.
aMultiple vessel disease included two and triple vessel disease and left 
main disease.
Table 4. Multiple binary logistic regression on risk of multiple 
vessel stenosis
OR 95% CI P value
Chemerin 1.018 0.997-1.040 0.091
Age 1.058 1.017-1.101 0.005
LDL 1.099 0.998-1.019 0.099
CRP 2.045 0.735-5.691 0.171
OR, odds ratio; CI, confidence interval; LDL, low density lipoprotein; 
CRP, C-reactive protein.252
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important role in the development of coronary artery disease 
in patients with metabolic syndrome [8-13]. Recent studies 
have shown that chemerin levels associate significantly with 
metabolic components of the metabolic syndrome [19,22,23]. 
However, whether chemerin levels are also associated with 
cardiovascular parameters in patients with coronary artery 
disease remains to be elucidated. In this study, we investigated 
whether circulating chemerin concentrations correlate with 
the cardiometabolic parameters of Korean patients with coro-
nary artery disease. We observed that serum chemerin con-
centrations were positively correlated with fasting glucose, tri-
glyceride, total cholesterol, LDL-cholesterol, and hsCRP. Se-
rum chemerin concentrations also had a significant correla-
tion with the degree of coronary artery stenosis, although we 
recognize this association was weak. 
  Chemerin is a recently identified chemoattractant protein 
that induces leukocyte migration; in addition, its receptor is 
expressed by tissue macrophages [16-18]. These observations 
suggest that chemerin functions in the development of inflam-
matory diseases, including atherosclerosis. In this study, we 
found that chemerin levels correlated positively with hsCRP 
levels. hsCRP is a circulating marker of inflammation that is 
predominantly produced by the liver in response to IL-6 [24]. 
Patients with metabolic syndrome have higher CRP levels than 
healthy individuals, and this high CRP level is an independent 
risk factor for type 2 diabetes and cardiovascular disease [24-
26]. CRP also directly promotes the inflammatory component 
of atherosclerosis by inducing adhesion molecule expression 
by human endothelial cells [27]. Recently, Lehrke et al. [22] 
analyzed the relationship between chemerin and metabolic 
components in patients with chest pain. In their study, chemer-
in is associated with coronary plaque burden and the number 
of non-calcified plaques, but these correlations dropped out 
after adjusting for other cardiovascular risk factors. In contrast 
to their study, this report shows that there was a significant but 
weak correlation between chemerin concentrations and the 
degree of coronary artery stenosis even after adjusting for oth-
er factors. Moreover, the group with multiple vessel disease 
had higher chemerin levels than the group with one vessel dis-
ease. Thus, our study suggests the possibility that chemerin 
could be associated with coronary artery disease; however our 
study did not show that chemerin level was not an indepen-
dent risk factor in multiple vessel disease.
  In addition to having pro-inflammatory effects, chemerin is 
a novel adipokine that has been associated with metabolic syn-
drome phenotypes [22]. Chemerin has been shown to regulate 
adipocyte differentiation and the expression of adipocyte genes 
involved in glucose and lipid homeostasis [19]. While Bozaog-
lu et al. [19] previously failed to detect a significant difference 
in the chemerin levels of subjects with normal glucose toler-
ance and subjects with type 2 diabetes, obese subjects were 
found to have significantly higher chemerin levels than lean 
subjects. Moreover, the chemerin levels in normal glucose-tol-
erant subjects were found to correlate significantly with vari-
ous metabolic parameters, including BMI, waist circumfer-
ence, waist-hip ratio, fasting glucose levels, fasting insulin lev-
els, plasma triglyceride levels, and blood pressure [19]. How-
ever, this study shows that while serum chemerin concentra-
tions significantly but weakly correlated with fasting glucose, 
triglyceride, total cholesterol and LDL cholesterol levels, they 
did not correlate with fasting insulin levels, HOMA-IR, BMI, 
waist circumference or blood pressure. This discrepancy may 
be due to differences between the study populations of the pre-
vious study and our own. In particular, our study included sub-
jects who were taking antihypertensives, oral hypoglycemia 
agents and statins. 
  This study has certain limitations that we will address here. 
First, we measured the number of significant coronary steno-
ses without individualizing each coronary stenosis according 
to the type of lesion involved. If we had done so, we could have 
obtained a more accurate correlation between chemerin and 
coronary stenosis (%). Second, we enrolled patients with sig-
nificant coronary artery stenosis (mentioned in Methods; >50% 
of patients) without enrolling healthy controls with no coro-
nary artery disease. Thus, we could not determine the odds ra-
tio of various cardiometabolic factors in coronary atheroscle-
rosis. Third, the chemerin ELISA kit used in this study mea-
sures full-length chemerin form. Chemerin protein exists as a 
full-length protein in plasma, but this form of the protein is 
known to have lower bioactivity than prochemerin [28]. How-
ever, despite these shortcomings, the results suggest that che-
merin could be useful as a predictor of metabolic syndrome 
and cardiovascular complications. 
  In conclusion, we found that circulating chemerin concen-
trations weakly but significantly correlated with several car-
diometabolic parameters as well as the severity of coronary ar-
tery stenosis in Korean patients with coronary artery disease. 
However, multivariate analysis showed chemerin was not an 
independent risk factor for multiple vessel disease. Additional 
investigations are necessary to fully elucidate the role chemer-253
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in plays in the development and/or progression of cardiovas-
cular disease. 
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